Choueri, T. K., Fishman, M. N., Escudier, B., McDermott, D. F., Kluger, H., Stadler, W. M., … Sznol, M. (2015). IMMUNOMODULATORY ACTIVITY OF NIVOLUMAB IN METASTATIC RENAL CELL CARCINOMA (MRCC): ASSOCIATION OF BIOMARKERS WITH CLINICAL OUTCOMES. Asia-Pacific Journal of Clinical Oncology, 11, 119–119.

Choueri, Toni K., Mayer N. Fishman, Bernard Escudier, David F. McDermott, Harriet Kluger, Walter M. Stadler, Jose L. Perez-Gracia, et al. “IMMUNOMODULATORY ACTIVITY OF NIVOLUMAB IN METASTATIC RENAL CELL CARCINOMA (MRCC): ASSOCIATION OF BIOMARKERS WITH CLINICAL OUTCOMES.” Asia-Pacific Journal of Clinical Oncology 11 (2015): 119–119.

Choueri TK, Fishman MN, Escudier B, McDermott DF, Kluger H, Stadler WM, et al. IMMUNOMODULATORY ACTIVITY OF NIVOLUMAB IN METASTATIC RENAL CELL CARCINOMA (MRCC): ASSOCIATION OF BIOMARKERS WITH CLINICAL OUTCOMES. Asia-Pacific Journal of Clinical Oncology. 2015;11:119–119.

Choueri, Toni K., et al. “IMMUNOMODULATORY ACTIVITY OF NIVOLUMAB IN METASTATIC RENAL CELL CARCINOMA (MRCC): ASSOCIATION OF BIOMARKERS WITH CLINICAL OUTCOMES.” Asia-Pacific Journal of Clinical Oncology, vol. 11, 2015, pp. 119–119.

Choueri TK, Fishman MN, Escudier B, McDermott DF, Kluger H, Stadler WM, Perez-Gracia JL, McNeel D, Curti B, Harrison MR, Plimack ER, Appleman L, Fong L, Drake CG, Young TC, Chasalow SD, Ross-Macdonald P, Simon JS, Walker D, Sznol M. IMMUNOMODULATORY ACTIVITY OF NIVOLUMAB IN METASTATIC RENAL CELL CARCINOMA (MRCC): ASSOCIATION OF BIOMARKERS WITH CLINICAL OUTCOMES. Asia-Pacific Journal of Clinical Oncology. 2015;11:119–119.